Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma ...Middle East

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation; key secondary endpoint of time to next intervention significantly improved in the vorasidenib arm...

Hence then, the article about servier presents transformational data from pivotal phase 3 indigo trial of vorasidenib in recurrent or residual grade 2 idh mutant diffuse glioma was published today ( Sunday 04/06/2023 - 03:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma )

Also on site :

• Man accused of placing pipe bombs near GOP and Democratic headquarters in Washington to remain in jail pending trial
• Aura AI Assistant for Unreal Engine Launches: VR Studio Ships Game in Half the Time with New Agent Capabilities
• Driver dies after plow truck goes off the road in Steuben County